Hong Kong’s main stock exchange actively recruits biotechnology firms as part of strategy to become Asia’s leading IPO destination. The successful Insilico Medicine listing in December showcased the exchange’s appeal, with additional European biotech companies now exploring Hong Kong as listing venue.
Source: FinanceAsia Read Full Story